1. Medtech Insight
  2. >>Archive

Acorn Cardiovascular Inc.

Acorn Cardiovascular Inc. has developed a device for the treatment of congestive heart failure. It operates under the same theory as cardiac wrapping, but is less invasive and less costly. Acorn's "jacket" made of synthetic fibers surrounds the heart and constrains it, preventing the cascade of progressive enlargement and weakening that accompanies CHF. According to Acorn's president and CEO Donald G. Rohrbaugh, the jacket's fibers are knitted into a unique configuration designed to conform closely to the heart's exterior. Special compliance properties provide uniform contact so that there are no particular stress points. During implantation, the device is tailored to provide a 5% reduction in the diameter of the heart. That reduction immediately helps to absorb some of the stress in the heart's wall and allows the myocardium to recover. "It's like providing an elastic sock on a tired leg muscle," says Rohrbaugh. "It absorbs some of those fatiguing stresses, and when the myocardium recovers, the heart is able to improve its contractility and relaxation properties so that it pumps more efficiently."

Five million Americans are living with congestive heart failure (CHF), and 400,000 new cases are diagnosed each year. The disease can be caused by a number of factors – infections, blockages, leaky valves, hypertension, or alcohol abuse— but the result is always the same. Damage to the heart muscle impairs its pumping ability, and the heart enlarges or "remodels" to compensate for the reduced blood output. This pattern is repeated, ultimately resulting in a balloon-shaped heart that is too weak to support life. The New York Heart Association has developed a classification system for CHF, with Class I being the mildest, Class IV the most severe. Patients in the earliest stages of the disease have a 50% chance of dying within five years, and only 15% of patients diagnosed with CHF survive more than ten.

There is no cure for CHF, only therapies for controlling its symptoms. Heart transplant, the most definitive therapy, is available...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.